BioCentury | Aug 22, 2019
Tools & Techniques

Digital makes its mark on cognition

...using Winterlight’s Speech Assessment tool as an exploratory endpoint in a Phase II/III trial testing COR388...
...tests of cognition. The partners first used Speech Assessment in Cortexyme’s Phase Ib trial testing COR388...
BioCentury | May 9, 2019
Finance

Cortexyme’s first-day pop leads IPO quartet amid choppy market

...in the brain by the bacteria Porphyromonas gingivalis, to treat Alzheimer’s disease. Its lead asset, COR388...
BioCentury | Mar 23, 2019
Product Development

Baby steps beyond beta amyloid

...vascular agents represent 41% of agents against newer targets for AD. The most advanced is COR388...
...Cortexyme Inc., which is in a Phase II/III trial to treat mild to moderate AD. COR388...
BioCentury | Jan 25, 2019
Clinical News

Cortexyme's bacterial protease inhibitor improves AD signs in mice

...Advances paper that lead product, COR388, slowed neurodegeneration in a mouse model of Alzheimer's disease. COR388...
...produced by the periodontitis-causing P. gingivalis . In a model of P. gingivalis -induced AD, COR388...
...AD. Cortexyme Inc., South San Francisco, Calif. Product: COR388 Business: Neurology Indication: Treat Alzheimer's disease Sandi Wong COR388 Cortexyme Beta...
BioCentury | Jan 24, 2019
Preclinical News

Cortexyme's bacterial protease inhibitor improves AD signs in mice

...Advances paper that lead product, COR388, slowed neurodegeneration in a mouse model of Alzheimer's disease. COR388...
...produced by the periodontitis-causing P. gingivalis . In a model of P. gingivalis -induced AD, COR388...
...plans to start a Phase II/III trial next quarter of COR388 to treat mild-to-moderate AD. Sandi Wong COR388 Cortexyme Beta...
BioCentury | Jun 1, 2018
Finance

Bacterial brain

...Inc. (NYSE:PFE), Takeda Ventures, Lamond Family, Breakout Ventures and Dolby Family Ventures. Cortexyme’s lead candidate, COR388...
...round in January 2016 and began dosing healthy volunteers in a Phase I trial of COR388...
...trial of COR388 in AD, which is slated to start next year. Jaime de León, Staff Writer COR388 Sequoia...
BioCentury | Jun 1, 2018
Financial News

Sequoia leads Cortexyme's $76M series B

...Next year, the company plans to start a Phase II proof-of-concept trial of lead candidate COR388...
...in a series A round led by Pfizer. Cortexyme Inc., South San Francisco, Calif. Jaime De Leon COR388 Breakout...
BioCentury | May 31, 2018
Financial News

Sequoia leads Cortexyme's $76M series B

...Next year, the company plans to start a Phase II proof-of-concept trial of lead candidate COR388...
...In 2016, Cortexyme raised $15 million in a series A round led by Pfizer. Jaime De Leon COR388 Breakout...
Items per page:
1 - 8 of 8